[1] Abdelmalek MF. Nonalcoholic fatty liver disease: another leap forward. Nat Rev Gastroenterol Hepatol, 2021, 18(2):85-86. [2] 王梦雨, 杨蕊旭, 范建高. 重视代谢相关脂肪性肝病的特征与预后临床研究. 实用肝脏病杂志, 2021, 24(3):308-311. [3] Makri E, Goulas A, Polyzos SA. Epidemiology, pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease. Arch Med Res, 2020, 52(1):25-37. [4] Cariou B, Byrne CD, Loomba R, et al. Nonalcoholic fatty liver disease as a metabolic disease in humans: a literature review. Diabetes Obes Metab, 2021, 23(5):1069-1083. [5] 潘哲, 张文富, 吕建林, 等. 脂必泰胶囊治疗非酒精性脂肪肝临床研究. 中华中医药学刊, 2020, 38(11):78-80. [6] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会, 范建高, 等. 非酒精性脂肪性肝病防治指南(2018年更新版). 实用肝脏病杂志, 2018, 21(2):30-39. [7] Wong WK, Chan WK. Nonalcoholic fatty liver disease: a global perspective. Clin Ther, 2021, 43(3):473-499. [8] Chen Z, Liu J, Zhou F, et al. Nonalcoholic fatty liver disease: an emerging driver of cardiac arrhythmia. Circ Res, 2021, 128(11):1747-1765. [9] Wang YL, Wu J, Li RX, et al. A double-edged sword: The Kelch-like ECH-associated protein 1-nuclear factor erythroid-derived 2-related factor 2-antioxidant response element pathway targeted pharmacological modulation in nonalcoholic fatty liver disease. Curr Opin Pharmacol, 2021, 60:281-290. [10] Zhang Y, Lyu J, Zhang J, et al. Lipidomic-based investigation into the therapeutic effects ofpolyene phosphatidylcholine and Babao Dan on rats with non-alcoholic fatty liver disease. Biomed Chromatogr, 2022, 36(2):e5271. [11] 王慧, 王小翠, 童强,等. 利拉鲁肽联合多烯磷脂酰胆碱对NAFLD患者血清抗氧化及炎性因子水平的影响. 重庆医学, 2021, 50(2):234-237. [12] Chen M, Li Y, Men L, et al. Efficacy and safety of Zhibitai in treating coronary heart disease patients with hyperlipemia: A protocol for systematic review and meta-analysis. Medicine, 2020, 99(36):e21991. [13] Xu G, Lin M, Dai X, et al. Comparing the effectiveness of Chinese patent medicines containing red yeast rice on hyperlipidaemia: A network meta-analysis of randomized controlled trials. Endocrinol Diabetes Metab, 2021, 5(1):e00314. [14] 王新强, 蒋虎刚, 赵信科,等. 脂必泰胶囊治疗血脂异常有效性及安全性的Meta分析. 中药药理与临床, 2021, 37(1):193-198. [15] 廖媛, 池晓玲, 吴宇金, 等. 脂必泰对非酒精性脂肪肝病大鼠模型疗效评价. 中国医院药学杂志, 2020, 40(22):2317-2321, 2326. [16] Zhao Y, Peng R, Zhao W, et al. Zhibitai and low-dose atorvastatin reduce blood lipids and inflammation in patients with coronary artery disease. Medicine, 2017, 96(7):e6104. [17] Zhang Y, Li JX, Zhang Y, et al. Intestinal microbiota participates in nonalcoholic fatty liver disease progression by affecting intestinal homeostasis. World J Clin Cases, 2021, 9(23):6654-6662. [18] Han H, Jiang Y, Wang M, et al. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis. Crit Rev Food Sci Nutr, 2021, 18:1-18. [19] Mehal WZ, Schwabe RF. A disease-promoting role of the intestinal mycobiome in non-alcoholic fatty liver disease. J Hepatol, 2022, 76(4):765-767. [20] Maurice J, Manousou P, Maurice J, et al. Non-alcoholic fatty liver disease. Clin Med (Lond),2018,18(3):245-250. |